Literature DB >> 7798653

Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine.

S Nader1, R Bergen, M Sharp, A M Arvin.   

Abstract

Live attenuated varicella vaccine elicits protection against varicella-zoster virus (VZV), but adults require two doses to achieve optimal seroconversion rates. To assess the potential role of cell-mediated immunity (CMI), T cell proliferation to VZV antigen was compared in children and adults. Mean stimulation indices (SI) in two cohorts of 39 children tested 6 weeks after vaccination were 28.6 +/- 6.21 and 22.1 +/- 3.84, whereas 20 adult vaccines had a mean SI of 9.1 +/- 0.99 (P = .04). Vaccinees had significant increases in CMI after a second dose of vaccine. At 1 year, VZV CMI was significantly lower in adults after two doses (10.0 +/- 1.13 vs. 15.6 +/- 1.77; P = .02), even though 82% of children received one dose. Limitations in the adult helper T cell response to VZV antigens may explain the need for booster doses to elicit effective immunity and the more frequent occurrence of varicella when adult vaccines are exposed to wild type virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7798653     DOI: 10.1093/infdis/171.1.13

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination.

Authors:  Christiane S Eberhardt; Andreas Wieland; Tahseen H Nasti; Alba Grifoni; Elizabeth Wilson; D Scott Schmid; Bali Pulendran; Alessandro Sette; Edmund K Waller; Nadine Rouphael; Rafi Ahmed
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 2.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

3.  Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Authors:  Markus Knuf; Fred Zepp; Klaus Helm; Hartwig Maurer; Albrecht Prieler; Dorothee Kieninger-Baum; Martine Douha; Paul Willems
Journal:  Eur J Pediatr       Date:  2011-09-21       Impact factor: 3.183

Review 4.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

5.  Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.

Authors:  Kareem Jamani; Judy MacDonald; Martin Lavoie; Tyler S Williamson; Christopher B Brown; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Peter Duggan; Jason Tay; Douglas Stewart; Andrew Daly; Jan Storek
Journal:  Blood Adv       Date:  2016-11-30

6.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

7.  Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.

Authors:  Pritish K Tosh; Richard B Kennedy; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

Review 8.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 9.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Age and immune status of rhesus macaques impact simian varicella virus gene expression in sensory ganglia.

Authors:  Christine Meyer; Jesse Dewane; Amelia Kerns; Kristen Haberthur; Alex Barron; Byung Park; Ilhem Messaoudi
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.